

## MEDIA RELEASE

# Cordlife Hong Kong is accredited by AABB for 13 consecutive years

- Cordlife Hong Kong has successfully passed AABB's sixth inspection since the first in 2011.
- AABB is internationally recognised as the leading organisation for the development of blood banking, transfusion medicine, blood management and cellular therapy standards.
- The accreditation is a validation to the Group's commitment to uphold and provide the highest standard of care to families worldwide.

**SINGAPORE, 8 June 2022** – Cordlife Group Limited ("**Cordlife**", together with its subsidiaries, the "**Group**"), a Singapore Exchange mainboard listed company, is pleased to announce that its wholly-owned Hong Kong subsidiary, Cordlife (Hong Kong) Limited ("**Cordlife Hong Kong**" or the "**Company**"), has been re-accredited by the AABB for the 13<sup>th</sup> consecutive year.

Since its inception in 1957, AABB is internationally recognised as the global leader in developing standards for blood banking, transfusion medicine, blood management and cellular therapies. AABB accreditation is the result of an intensive assessment by specially trained assessors who evaluate internal policies and procedures and determine whether the facility's level of medical, technical and administrative performance meets or exceeds the AABB standards. The evaluation covers every aspect of cord blood banking, including cord blood collection, transportation, receiving, processing, cryopreservation and release.

"We are pleased that Cordlife Hong Kong has been re-accredited by the AABB," said Ms Tan Poh Lan, Executive Director and Group CEO of Cordlife Group Limited. "The accreditation gives us confidence that we are on the right track in terms of patient safety, giving peace of mind to Hong Kong families who have banked their baby's cord blood with us."

Cordlife also has other Hong Kong subsidiaries that are accredited by other quality standards such as the Foundation for the Accreditation of Cellular Therapy ("**FACT**") and the College of American Pathologists ("**CAP**"), demonstrating the Group's dedication to patient safety and quality.

**### End ###**



## ABOUT AABB

AABB (Association for the Advancement of Blood & Biotherapies) is an international, not-for-profit organization representing individuals and institutions involved in the fields of transfusion medicine and biotherapies. The Association works collaboratively to advance the field through the development and delivery of standards, accreditation and education programs. AABB is dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available and effective worldwide. For more information, please visit [www.aabb.org](http://www.aabb.org)

## ABOUT CORDLIFE GROUP LIMITED

Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, is a leading company dedicated to safeguarding the well-being of mother and child. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia. Cordlife operates Asia’s largest network of cord blood banks. With full stem cell banking facilities in six key markets, Cordlife is an industry leader in Singapore, Hong Kong, Indonesia and the Philippines, and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. In addition to cord blood, cord lining, cord tissue and lenticule banking, Cordlife offers families a comprehensive suite of diagnostics services, including non-invasive prenatal testing, paediatric vision screening and newborn metabolic screening. Two of Cordlife’s primary focus areas are providing reliable quality and being customer-centric. All of the Group’s facilities are accredited by the Association for the Advancement of Blood & Biotherapies (“AABB”), an organisation dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available and effective worldwide. Furthermore, Cordlife Singapore and Healthbaby Hong Kong are the only two full-fledged private cord blood banks in Asia and five worldwide to be accredited by both AABB and the Foundation for the Accreditation of Cellular Therapy (“FACT”), another world-class accreditation body for cord blood banks worldwide. In the area of clinical diagnostics, Cordlife India, Cordlife Hong Kong and Healthbaby Hong Kong are all accredited by the College of American Pathologists (“CAP”). This makes Healthbaby Hong Kong the only private cord blood bank in the world to be accredited by three international standard-setting bodies, and Cordlife India one of the only two medical laboratories in West Bengal to be holding accreditations from the National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and CAP. These quality achievements reinforce the Group’s commitment to providing reliable healthcare solutions through innovation and technological advancement. For more information, visit <http://cordlife.listedcompany.com>.

---

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Financial PR  
4 Robinson Road #04-01  
The House of Eden  
Singapore 048543



CONTACT : Mr Maverick Lim  
OFFICE : (65) 9272 1071  
EMAIL : maverick@financialpr.com.sg